C12N 2720/12111
Orbivirus
Official title: Orbivirus, e.g. bluetongue virus
C12N2720/12111 (Orbivirus) appears on 32 US grants and 33 published applications in this corpus.
Search patents in C12N- Granted patents
- 32
- Published applications
- 33
- Assignees
- 34
- Inventors
- 79
- Latest grant
- 2 Dec 2025
Filings by year
| Year | Granted patents | Published applications |
|---|---|---|
| 1978 | 1 | 0 |
| 1979 | 0 | 0 |
| 1980 | 0 | 0 |
| 1981 | 0 | 0 |
| 1982 | 0 | 0 |
| 1983 | 0 | 0 |
| 1984 | 0 | 0 |
| 1985 | 1 | 0 |
| 1986 | 0 | 0 |
| 1987 | 2 | 0 |
| 1988 | 0 | 0 |
| 1989 | 0 | 0 |
| 1990 | 0 | 0 |
| 1991 | 0 | 0 |
| 1992 | 1 | 0 |
| 1993 | 1 | 0 |
| 1994 | 0 | 0 |
| 1995 | 0 | 0 |
| 1996 | 0 | 0 |
| 1997 | 2 | 0 |
| 1998 | 3 | 0 |
| 1999 | 1 | 0 |
| 2000 | 0 | 0 |
| 2001 | 0 | 0 |
| 2002 | 0 | 0 |
| 2003 | 0 | 0 |
| 2004 | 0 | 0 |
| 2005 | 0 | 0 |
| 2006 | 0 | 0 |
| 2007 | 0 | 2 |
| 2008 | 0 | 0 |
| 2009 | 0 | 0 |
| 2010 | 0 | 2 |
| 2011 | 1 | 5 |
| 2012 | 1 | 1 |
| 2013 | 0 | 3 |
| 2014 | 1 | 2 |
| 2015 | 1 | 1 |
| 2016 | 2 | 2 |
| 2017 | 1 | 2 |
| 2018 | 2 | 1 |
| 2019 | 0 | 3 |
| 2020 | 2 | 2 |
| 2021 | 4 | 3 |
| 2022 | 1 | 0 |
| 2023 | 1 | 0 |
| 2024 | 1 | 1 |
| 2025 | 2 | 1 |
| 2026 | 0 | 2 |
By publication year. Applications have been published since 2001. 2026 runs to 8 Oct.
Subgroups
Granted patents
- C12N 2720/12134Use of virus or viral component as vaccineIndexing code21
- C12N 2720/12122New viral proteins or individual genes, new structural or functional aspects ofIndexing code10
- C12N 2720/12161Methods of inactivation or attenuationIndexing code8
- C12N 2720/12151Methods of production or purification of viral materialIndexing code6
- C12N 2720/12141Use of virus, viral particle or viral elements as a vectorIndexing code5
- C12N 2720/12171Demonstrated in vivo effectIndexing code5
- C12N 2720/12121Viruses as suchIndexing code4
- C12N 2720/12123Virus like particles [vlp]Indexing code3
All 12 subgroupsShow fewer
Recent patents
- Cancer therapy compositions and uses thereof2 Dec 2025US 12,485,163 B2HDT Bio Corp.
- Plant-produced chimaeric orbivirus VLPs4 Feb 2025US 12,215,328 B2Csir
- Mammal-specific growth-defective arbovirus24 Sep 2024US 12,098,393 B2TenGen Biomedical Company
- Recombinant modified vaccinia virus ankara (MVA) equine encephalitis virus vaccine7 Feb 2023US 11,571,471 B2Bavarian Nordic A/S
- Epizootic hemorrhagic disease virus—tel aviv university (EHDV-TAU)—oncolytic virus for treating cancer1 Nov 2022US 11,484,558 B2Ramot at Tel-Aviv University Ltd.
- Mrna recombinant capping enzymes16 Jul 2026US 2026/0201350 A1Sanofi Pasteur Limited
- Cancer therapy compositions and uses thereof19 Feb 2026US 2026/0048108 A1HDT Bio Corp.
- Plant-produced chimaeric orbivirus vlps19 Jun 2025US 2025/0197874 A1Csir
- Cancer therapy compositions and uses thereof4 Jul 2024US 2024/0216493 A1HDT Bio Corp.
- Plant-produced chimaeric orbivirus vlps16 Dec 2021US 2021/0388366 A1Csir
Most cited
By later US patents
- Preparation of inactivated viral vaccines92US 4,693,981 AAdvanced Genetics Research Institute · 1987
- Synthesis and immunogenicity of rotavirus genes using a baculovirus expression system81US 5,891,676 ABaylor College of Medicine · 1999
- Synthesis and immunogenicity of rotavirus genes using a baculovirus expression system78US 5,843,733 ABaylor College of Medicine · 1998
- Preparation of inactivated viral vaccines49US 5,106,619 ADiamond Scientific Co. · 1992
- Psoralen inactivated double-stranded RNA viral vaccines23US 4,545,987 AAdvanced Genetics Research Institute · 1985